Table 4.
Univariate Analysis for Prognostic Factors in PSM Analysis (n = 142).
| Variable | HR | 95% CI | P | Variable | HR | 95% CI | P |
|---|---|---|---|---|---|---|---|
| NAC regimen | <0.001 | Age (ys) | 0.271 | ||||
| NIPS | 0.520 | 0.360-0.750 | <40 | 0.653 | 0.388-1.098 | ||
| NSC | Ref | 41-59 | 0.817 | 0.540-1.238 | |||
| Gender | 0.844 | 60-75 | Ref | ||||
| Male | 0.964 | 0.669-1.390 | cT stage | <0.001 | |||
| Female | Ref | T3 | 0.106 | 0.053-0.210 | |||
| PS score | <0.001 | T4a | 0.361 | 0.220-0.592 | |||
| 0 | 0.522 | 0.362-0.752 | T4b | Ref | |||
| 1 | Ref | P stage | <0.001 | ||||
| cN stage | <0.001 | P0CY1 | 0.020 | 0.004-0.089 | |||
| N0 | 0.160 | 0.073-0.349 | P1 | 0.152 | 0.081-0.287 | ||
| N1 | 0.351 | 0.198-0.625 | P2 | 0.433 | 0.244-0.770 | ||
| N2 | 0.917 | 0.530-1.589 | P3 | Ref | |||
| N3 | Ref | Tumor response | <0.001 | ||||
| Ascites volume | <0.001 | CR | 0.060 | 0.018-0.199 | |||
| None | 0.137 | 0.054-0.346 | PR | 0.156 | 0.073-0.336 | ||
| + | 0.246 | 0.122-0.497 | SD | 0.279 | 0.130-0.597 | ||
| ++ | 0.265 | 0.131-0.533 | PD | Ref | |||
| +++ | Ref | Ascites response | <0.001 | ||||
| Cytology response | <0.001 | Disappearance | 0.018 | 0.007-0.043 | |||
| Negative | 0.096 | 0.058-0.161 | Decreased | 0.053 | 0.024-0.118 | ||
| Positive | Ref | Stable | 0.321 | 0.156-0.662 | |||
| Conversion surgery | <0.001 | Progression | Ref | ||||
| No | Ref | R0 resection | <0.001 | ||||
| Yes | 0.031 | 0.015-0.063 | No | Ref | |||
| Complication | 0.006 | Yes | 0.017 | 0.006-0.046 | |||
| No | 0.402 | 0.211-0.767 | |||||
| Yes | Ref | ||||||
Abbreviations: PSM, propensity score matching; NAC, neoadjuvant chemotherapy; NIPS, neoadjuvant intraperitoneal and systemic chemotherapy; NSC, neoadjuvant systemic chemotherapy; PS, performance status; CR, complete response; PR, partial response; SD, stable disease; PD, progression disease; RR, response rate; DCR, disease control rate; HR, hazard ratio; Ref, reference; CI, confidence interval; +, <500 ml; ++, 500∼2000 ml; +++, >2000 ml.